1. Home
  2. News
  3. Argenica Therapeutics Ltd
  4. Topline Phase 2 Trial Results of ARG-007 in AIS Patients
More Argenica Therapeutics Ltd news
Argenica Therapeutics LtdASX: AGN

Topline Phase 2 Trial Results of ARG-007 in AIS Patients

Sep 2, 2025 at 11:55 PM EDT · Issued by Argenica Therapeutics Ltd

Filed with ASX · Sep 2, 2025 at 11:55 PM EDT · 7 pages · English

On 6ix: 6ix.com/news/topline-phase-2-trial-results-of-arg-007-in-ais-patients

Argenica Therapeutics Ltd on 6ix

In the deck

  • Argenica Therapeutics — Investor Presentation (September 2025)16 slidesSep 3, 2025

Story so far

  • Last Patient Dosed in Phase 2 Stroke TrialApr 11, 2025
  • Positive DSMB Safety Outcome & Phase 2 Trial Progress UpdateJan 30, 2025
  • Phase 2 Stroke Clinical Trial UpdateDec 10, 2024

Earlier from Argenica Therapeutics

  • Trading HaltAug 31, 2025
  • Appendix 4E & Annual Report to 30 June 2025Aug 28, 2025
  • Argenica Receives IND Feedback From FDAAug 13, 2025
  • Argenica Awarded Federal Government FundingJun 20, 2025
  • Argenica to Progress Clinical Development in TBIJun 17, 2025

Later from Argenica Therapeutics

  • Phase 2 Trial Promising Improvements in Functional OutcomesOct 14, 2025
  • ARG-007 Efficacious Dose Validated in New Preclinical StudyNov 24, 2025
  • Positive TNK Study Results Fulfil Key FDA RequirementDec 3, 2025
  • AI Analysis Reveals Efficacy In Severe Stroke PatientsDec 10, 2025
  • Quarterly Activities/Appendix 4C Cash Flow ReportJan 27
All Argenica Therapeutics news releases↗

Follow Argenica Therapeutics into a list and get an email when it puts out news.

Follow Argenica Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer